Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
144
resultados
Última actualización
16/04/2026 [07:37:00]
Resultados 75 a 100 de 144
Resumen de: CN121087164A
The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.
Resumen de: CN121081471A
The invention relates to the field of biological pharmacy, and provides application of CHI3L1 in preparation of medicines for diagnosing and treating ulcerative colitis. The invention discloses an application of a CHI3L1 inhibitor (K284-6111) in development of a medicine for preventing and treating UC, and an application of a reagent for detecting the expression level of CHI3L1 in development of a UC diagnostic tool. The effect of K284-6111 in UC treatment is explored through a DSS-induced mouse model, and a new UC treatment method is provided. The invention provides a high-specificity biomarker for UC diagnosis and application of the high-specificity biomarker in UC prevention and treatment.
Resumen de: CN121065326A
The invention discloses an intestinal flora marker related to metabolic heterogeneity of azathiopurine (AZA) and application of the intestinal flora marker, and belongs to the technical field of personalized drug treatment of inflammatory bowel diseases (IBD). In particular, the invention finds that a specific intestinal flora marker is significantly related to the level of an AZA active metabolite 6-thiopurine nucleotide (6-TGN). For example, the prevotella abundance can be used for distinguishing IBD patients with different 6-TGN exposure levels, has an indication effect on the in-vivo 6-TGN concentration, and has an important application value in thiazopurine therapeutic drug monitoring (TDM). In addition, clostridium species Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are significantly enriched in a 6-TGN high-exposure patient group, and the microbiome of the clostridium sp.OF09-36 and Clostridium sp.AF32-12BH encodes enzyme genes participating in purine metabolism, such as GMPS, HPRT, IMPDH and the like, which indicate that the Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are potential intestinal flora targets for regulating and controlling AZA metabolism. The intestinal flora marker provided by the invention provides a new biomarker and an intervention target for optimization and adjustment of AZA therapeutic dose and individualized precise treatment of IBD.
Resumen de: AU2024273758A1
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
Resumen de: US2025366831A1
A system and a method for diagnosis and monitoring of inflammatory bowel diseases (IBD) in a subject are provided. The system includes a memory and a control system. The memory stores machine-readable instructions. The control system includes one or more processors configured to execute the machine-readable instructions. Ultrasound image data associated with the gastrointestinal tract of the subject is received. The received ultrasound image data is processed to output a set of ultrasound image features. The output set of ultrasound image features is received, as an input to an automated algorithm. A set of radiomic features is extracted from the input set of ultrasound image features, using the automated algorithm. The ultrasound image data is classified as normal or abnormal based on the extracted set of radiomic features, the classifying being an output of the automated algorithm.
Resumen de: WO2025250163A1
Apparatus and associated methods relate to evaluating impurity content in battery materials. In an illustrative example, a battery material impurity assessment system (BMIAS) may include a slurry mixing system and an impurity extraction system (IBS). The slurry mixing system, for example, may include a motor configured to rotate a vertical axis of a slurry container. For example, the motor may pause a movement of the slurry container when the vertical axis is rotated at a predetermined angle. For example, the IBS may include a translatable magnetic mass (TMM) enclosed within a sheath. For example, by operating a position of the TMM, the IBS may release non-target impurity and retain target substances. In some implementations, the target substance may be ionized by an acid treatment solution rapidly without direct heating. In some implementations, the target substances may be dispersed on a conductive filter to be directly used in subsequent analysis. Various embodiments may advantageously rapid high precision and rapid impurity testing for battery manufacturing.
Resumen de: WO2024156739A1
The invention relates to a method for identifying a multi-parameter phenotype of microbiota. The method comprises (i) providing a sample comprising microbiota, (ii) labeling said microbiota with multiple labels, each of which binds a phenotypic parameter of said microbiota, (iii) detecting an intensity of the labelled phenotypic parameters of single cells of the microbiota by flow cytometry, and (iv) segmenting the single cells into bins based on the intensities of detected phenotypic parameters, wherein the distribution of single cells in bins represents a multi-parameter phenotype of said microbiota. The invention further relates to a system for identifying a multi-parameter phenotype of intestinal microbiota, a kit for identifying a multi-parameter phenotype of intestinal microbiota and methods for diagnosing a medical condition associated with microbiota, for example an inflammatory condition, such as an inflammatory bowel disease, in a subject.
Resumen de: CN121049497A
一种均相检测体系，包括能量供体和能量受体，所述能量供体和所述能量受体的信号源至少有两种，所述信号源的可区分度包括激发波长、发射波长和/或发光寿命。由于信号源至少有两种，使得至少有两种不同的待测样本可以被同时测量，当信号源满足合适的条件，不同种类的敏化剂按照不同的比例混合，则其激发波长可以覆盖全色域。因而在均相检测时，任何待检测样本在通量满足的前提下均可以一次性检测完毕，只需要光源按照既定的程序全波段闪烁激发。既可以实现相同样本的高通量检测，也可以实现不同样本的一次性检测，提高了检测效率。
Resumen de: CN121041328A
The invention belongs to the field of biological medicines, and particularly relates to application of Clostridium baumannii in preparation of a product for treating and/or preventing inflammatory bowel diseases.
Resumen de: MX2025010187A
Described herein are methods of reducing CD3-dependent T cell signaling in a subject in need thereof. Also described are method of increasing T-regulatory (Treg) cells, or decreasing T-helper 17 (Th17) cells. These methods involve administering butyrophilin A2 (BTN2A2), a BTN2A2 fragment thereof, a BTN2A2-related isoform, or a BTN2A2-related isoform fragment, or a conjugate or fusion polypeptide comprising any of the foregoing to the subject. These methods are beneficial for patients with autoimmune disorders and inflammatory disorders such as allergy, asthma, glomerulonephritis, inflammatory bowel disease, rheumatoid arthritis, an autoimmune or inflammatory neurological disease, antibody mediated transplant rejection, infantile cholestasis, haemophagocytic lymphohistiocytosis, erythrocytic haemophagocytosis, malnutrition, systemic lupus erythematosus (lupus), psoriasis, myasthenia gravis or HIV. Further described are fusion proteins having BTN2A2 and an Fc domain.
Resumen de: NZ762152A
The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a truncated human Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) protein. The disclosure also provides isolated and recombinant human SIGIRR protein variants that comprise a truncation at a position corresponding to position 215. The truncation, and the nucleic acid molecules encoding this change, associate with early-onset inflammatory bowel disease (EO-IBD). The disclosure also provides methods for determining whether a subject has or has a risk of developing EO-IBD, based on the identification of such alterations in the nucleic acid molecules encoding SIGIRR.
Resumen de: CN121015828A
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a heat-purging stagnation-removing traditional Chinese medicine compound preparation and a preparation method and application thereof. The traditional Chinese medicine compound preparation for purging heat and removing stagnation is prepared from the following raw materials in parts by weight: 10-60 parts of radix bupleuri, 10-30 parts of radix scutellariae, 10-30 parts of radix paeoniae rubra, 10-30 parts of rhizoma pinelliae preparata, 10-40 parts of fresh ginger, 10-40 parts of fructus aurantii, 10-40 parts of cortex mori radicis, 10-30 parts of peach kernels, 10-30 parts of liquorice, 1-15 parts of cassia twig, 10-30 parts of fructus forsythiae, 1-15 parts of rhizoma cimicifugae and 8-30 parts of honeysuckle. The traditional Chinese medicine compound preparation for purging heat and removing stagnation is a self-formulated formula, takes bowel purging, heat purging, blood circulation promoting and blood stasis removing as main treatment methods, improves clinical symptoms of patients suffering from systemic inflammatory reaction, reduces the incidence rate of multi-organ dysfunction, and improves the living quality and prognosis of the patients.
Resumen de: WO2025244478A1
The present invention relates to a novel microorganism and a use thereof for preventing, alleviating, or treating intestinal diseases. The strain according to one embodiment has effects of inhibiting intestinal atrophy and reducing bloody stools, and thus is useful for the prevention, amelioration, or treatment of intestinal diseases. In addition, since the strain is significantly reduced in the patient group, the strain can be used for early diagnosis of intestinal diseases or selection of a risk group.
Resumen de: WO2025245006A1
Provided herein arc systems and methods for testing exhaled breath from a subject (e.g., suspected of having inflammatory bowel disease, IBD) to determine the level of at least one volatile organic compound (e.g., 1 or 5 or 8 compounds). In certain embodiments, one receives test results, such as an elevated or decreased level of a particular volatile organic compound, and this is used to determine if a subject has IBD or needs treatment with an IBD treating agent. In other embodiments, the subject is treated with an IBD treating agent, and optionally tested again to monitor treatment (e.g., tested over days, weeks, or months). In other embodiments, the subject is determined to have moderate or severe IBD, or mild or no IBD.
Resumen de: WO2025244988A1
Disclosed are methods of characterizing, diagnosing, monitoring, and/or treating an individual with Crohn's Disease (CD) comprising detecting, in a biological sample obtained from the individual, a plurality of biomarkers. The biomarkers may be used for one or more of predicting remission of CD in an individual, determining longitudinal assessment of response to a biologic therapy, predicting or determining response status of the individual to an anti-tumor necrosis factor (TNF) therapy. Further disclosed are systems and compositions for use with the disclosed methods.
Resumen de: US2025237665A1
A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohn's disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohn's disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: CN120983481A
The invention relates to an application of a Blautia pseudococcoides bacterium in preparation of a medicine for treating ulcerative colitis, in particular to an application of the Blautia pseudococcoides bacterium in preparation of a medicine for treating ulcerative colitis. Specifically, the invention provides an application of the Blauria pseudococcoides bacterium in preparation of a medicine for preventing and/or treating the inflammatory bowel disease, and the preservation number of the Blauria pseudococcoides bacterium is DSM26115. Furthermore, the present invention relates to a composition for diagnosing inflammatory bowel disease comprising an agent for measuring the level of enteric microorganisms, a kit comprising the composition, and a method for diagnosing inflammatory bowel disease comprising a step of measuring the level of enteric microorganisms.
Resumen de: AU2024265914A1
The present invention relates generally to methods and compositions for treating and/or preventing an inflammatory bowel disease (IBD) and perianal fistulas, the method comprising the administration of therapeutic cells in the subject in need thereof.
Resumen de: JP2025171299A
To provide: a technique that can predict the prognosis of inflammatory bowel disease, can contribute to verifying treatment effects at that point in time, imposes less physical burden, and has high accuracy (low likelihood of missing individuals at risk of worsening disease); and a technique that can contribute to diagnosing inflammatory bowel disease, imposes less physical burden, and enables inexpensive and rapid testing of the likelihood of contracting inflammatory bowel disease.SOLUTION: A method for predicting the prognosis of inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject. A method for testing inflammatory bowel disease comprises detecting the amount of an N-acetylneuraminate lyase gene derived from intestinal bacteria in a biological sample from a subject.SELECTED DRAWING: Figure 6
Resumen de: WO2025240975A1
Pulmonary arterial hypertension (PAH) exhibits an obliterative vasculopathy where complex, integrated pathobiological signaling pathways drive vascular remodeling. In PAH, the arteriopathy includes numerous endophenotypes that occur to differing extents across patients. Variability in the proteomic and genetic profile is observed, causing phenotypic heterogeneity and inconsistent clinical responses to drug therapies. We have used network medicine to discover modifiable therapeutic targets in PAH by generating patient-specific protein-protein interaction (PPI) networks to unmask molecular interactions that identify and distinguish groups of individual patients with the same clinical phenotype. This allows personalized clinical phenotyping in PAH in those patient groups. The findings here also clarify the relationship between PAH genetic risk and pathobiology on an individual patient level, and inform treatment rationales and personalized drug selection using the PPI networks. Overall, findings from this project will advance precision medicine in PAH with direct relevance to the clinical management of patients.
Resumen de: CN118581208A
The invention provides a marker for diagnosing systemic inflammation and application, the marker comprises ADGRE3mRNA or ADGRE3 protein, or ADGRE3mRNA fragment and ADGRE3 protein fragment, the marker content in samples of systemic inflammation patients and healthy people has significant difference, clinical verification shows that the marker is high in diagnosis sensitivity and specificity, and the marker can be applied to diagnosis of systemic inflammation. Therefore, systemic inflammation can be accurately diagnosed by detecting the transcription level of ADGRE3 mRNA or the expression level of ADGRE3 protein in an individual sample. Compared with an existing inflammation marker, the ADGRE3 mRNA and the ADGRE3 protein have higher sensitivity and specificity in the aspect of diagnosis of systemic inflammation.
Resumen de: TW202544255A
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Resumen de: CN120945033A
The invention discloses a tissue resident bacterium marker for identifying normal colorectal tissue, polyp and intestinal cancer and application of the tissue resident bacterium marker. According to the present invention, the tissue resident bacterium markers comprise Pseudomonas, Pigmentiphaga, Fusobacteria, Parabacteroides, Bacteroides, Collinsella and Parvimonas, and can be used to reflect the biological specificity of patients, and the biological specificity of the patients can be represented by the tissue resident bacterium markers, such that the biological specificity of the patients can be represented by the tissue resident bacterium markers, and the biological specificity of the patients can be represented by the tissue resident bacterium markers, such that the biological specificity of the patients can be represented by the tissue resident bacterium markers, and the biological specificity of the patients can be represented by the tissue resident bacterium markers; according to the present invention, with the combination model of the six bacteria such as Pseudomonas, Pigmentiphaga, Fusobacteria, Parabacteroides, Bacteroides and Collinsella, the normal tissue and polyp of the colorectum can be accurately identified, and the accuracy is improved by 12.5% compared with the accuracy of the existing non-invasive screening method; the polyp and the intestinal cancer can be more accurately identified by a combined model of four bacteria, namely, Pseudomonas, Pigmentiphaga, F
Resumen de: CN120958143A
The present invention provides compositions and methods for diagnosing disease, assessing disease activity, monitoring mucosal healing, and predicting therapeutic response using fecal-derived eukaryotic nucleic acid biomarkers. The biomarkers can be used by practitioners for better diagnosis, management and treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Nº publicación: WO2025232867A1 13/11/2025
Solicitante:
CENTRE FOR CHINESE HERBAL MEDICINE DRUG DEVELOPMENT LTD [CN]
CENTRE FOR CHINESE HERBAL MEDICINE DRUG DEVELOPMENT LIMITED
Resumen de: WO2025232867A1
A method for detecting anxiety and/or depression metabolic and microbiome markers in a patient with irritable bowel syndrome (IBS) is provided. The method begins with obtaining a serum sample and a fecal sample from the patient. Both samples are processed to extract a gut metagenome, including a bacteriome, a mycobiome, and a virome of the patient, and metabolic features. A classifier is utilized to detect whether a marker set of microbial species and metabolites for depression and anxiety is present in the gut metagenome and the metabolic features.
BOPI
Sede Electrónica
